Articles for author: Ron Finklestien

January 8, 2024

Ron Finklestien

Assessing Dave & Buster’s (PLAY) Investment — Wall Street’s Encouraging Stance Assessing Dave & Buster’s (PLAY) Investment — Wall Street’s Encouraging Stance

Brokers are a stock investor’s North Star. But, can the views of these Wall Street pros actually guide your investment moves? Before we delve into the reliability of broker recommendations and how to exploit them favorably, let’s peek into the sentiments echoing on the Street regarding Dave & Buster’s (PLAY). It comes as no surprise that Dave & Buster’s currently basks in the glow of an Average Brokerage Recommendation (ABR) of 1.38, a figure derived from the assessments of eight brokerage firms. On the brokerage scale of 1 to 5, which spans from Strong Buy to Strong Sell, this implies

January 8, 2024

Ron Finklestien

Why Kirby Corporation (KEX) Is a Compelling Investment Option Why Kirby Corporation (KEX) Is a Compelling Investment Option

Investors, listen up. Outstanding Performance and Future Potential Kirby Corporation (KEX) has been on a winning streak, and there’s every indication that this is just the beginning of its upward trajectory. If you’ve been waiting on the sidelines, now is your chance to dive into this winning stock. An Outperformer The stock’s astounding performance over the past year speaks volumes – a staggering 22% spike. It’s a visual feast, an unbridled spectacle on the bourse. Image Source: Zacks Investment Research Solid Zacks Rank: With a Zacks Rank #2 (Buy), Kirby stands as a shining star, beckoning investors with the promise of

January 8, 2024

Ron Finklestien

Dow Surges as Commercial Metals Posts Strong Q1 Results Dow Surges Over 100 Points; Commercial Metals Posts Upbeat Q1 Results

U.S. stocks capitalized on a surge in momentum Monday, with the Dow Jones index accelerating over 100 points during trading. The Dow soared 0.35% to 37,596.43, while the NASDAQ ascended 1.89% to 14,799.21. The S&P 500 also experienced a healthy rise, increasing by 1.11% to 4,749.41. Information technology shares flung themselves into the limelight, leaping by 2.1% on Monday. In contrast, energy shares stumbled, falling by 2.1%. Commercial Metals Company Commercial Metals Company CMC reported robust earnings for its first quarter on Monday, exceeding market expectations. The company delivered adjusted earnings of $1.63 per share, outperforming market estimates of $1.45

January 8, 2024

Ron Finklestien

Bristol-Myers looking for smaller deals after 2023 shopping spree: report

Bristol-Myers Embarks on Smaller Deals Strategy After 2023 Spree The Shift in Bristol-Myers Strategy Bristol Myers Squibb (NYSE:BMY) is set to unveil 16 new products by the close of the decade, marking a significant milestone for the pharmaceutical giant. However, the company is signaling a departure from its spree of major takeovers in 2023, aiming for smaller deals to strengthen its position in the market. Ceasing Pursuit of Major Takeovers The announcement was made by Bristol Myers CEO, Christopher Boerner, during the annual JP Morgan Healthcare Conference in San Francisco. Boerner expressed the company’s intention to shift gears from pursuing

January 8, 2024

Ron Finklestien

Wall Street Analysts’ Perspective on Super Micro’s Future Stock Performance Wall Street Analysts’ Perspective on Super Micro’s Future Stock Performance

Before diving into the reliability of brokerage recommendations, let’s take a look at what Wall Street analysts have to say about Super Micro Computer (SMCI). The Brokerage Verdict Super Micro currently boasts an average brokerage recommendation (ABR) of 1.57, indicating a consensus between Strong Buy and Buy, based on assessments from seven brokerage firms. Out of these seven recommendations, an overwhelming 71.4% vouch for a Strong Buy rating. Understanding Brokerage Recommendations While the ABR leans towards a favorable view of Super Micro, it is essential to exercise caution when solely relying on this metric for investment decisions. Numerous studies have

January 8, 2024

Ron Finklestien

UMH Properties Sees Escalating Occupancy and Rental Revenue Amidst Robust Demand

UMH Properties: A Recap of 2023 UMH Properties recently revealed its operational results for the year concluded in 2023, highlighting an upsurge in the demand for manufactured home communities. These results ushered in heightened occupancy and significant rent escalation over the course of the year. Notably, the company’s market capitalization surpassed the $1 billion mark at the conclusion of 2023. Although shares witnessed a slight dip during the normal trading session on the NYSE on Jan 5, UMH’s overall trajectory has been notably impressive. Substantial Growth and Strategic Vision During 2023, UMH Properties successfully rented out 1,040 new homes, elevating

January 8, 2024

Ron Finklestien

Ambrx Biopharma – A Rising Star Amidst Crude Oil’s Tumble

Market Overview The trading day saw mixed fortunes for U.S. stocks. The Nasdaq Composite displayed resilience, securing over a 1% gain on Monday. The Dow experienced a 0.19% dip, resting at 37,396.28, while the NASDAQ climbed 1.20% to 14,698.88. The S&P 500 also registered an upswing, notching a 0.55% gain to reach 4,722.93. Leading and Lagging Sectors Amidst the market turbulence, the information technology sector emerged as a frontrunner, witnessing a 2% surge on Monday. Conversely, energy shares bore the brunt of the trading day, experiencing a 2.2% decline. Exciting Developments Ambrx Biopharma Inc. AMAM seized the day with a

January 8, 2024

Ron Finklestien

The Surge of RxSight and Other Stocks Shaking Up the Market

RxSight, Inc.RXST soared during Monday’s session after the company released preliminary FY23 and FY24 revenue guidance that topped estimates. Additionally, Needham upped its price target on the stock from $35 to $41 while affirming a Buy rating. RxSight shares catapulted 20% to $44.31 on Monday. Here are some other stocks making waves in today’s mid-day session. The Winners Circle Harpoon Therapeutics, Inc. HARP surged 111.2% to $22.28 after Merck’s announcement of an acquisition at $23 per share in cash. Ambrx Biopharma Inc. AMAM leaped 98.1% to $27.00 following Johnson & Johnson’s all-cash merger for an equity value of roughly $2

January 8, 2024

Ron Finklestien

Verizon’s Stock Rally Comes to a Halt Amid Positive Projections Verizon’s Stock Rally Comes to a Halt Amid Positive Projections

photobyphm/iStock Editorial via Getty Images After an impressive six-day rally that saw a 7.75% surge, Verizon Communications (NYSE:VZ) shares were poised to experience their first decline since Dec. 27, 2023, inching 0.10% lower to $40.18 by 1327 ET on Monday. The telecommunications company attracted attention last week with upgrades from KeyBanc Capital Markets and Wolfe Research, attributed to the low competitive environment in the wireless industry and improving subscriber growth. Despite this pause, projections for Verizon remain promising. Barron’s reported that the stock’s adjusted EBITDA growth is expected to be 2% in 2024, compared to zero in 2023, marking the

January 8, 2024

Ron Finklestien

2024 Preview: Latin America VC Industry

This article is part of the LatAm Tech Weekly Series, written by Julia De Luca and powered by Nasdaq. Through Nasdaq’s global network, we partner with Latin American companies to support their entire business lifecycle to elevate their brand and access the global markets. Learn more about Latin American Listings here. I’m excited to greet you for the first LatAm Tech Weekly of 2024. This week’s edition is quite special as I delve into an insightful analysis offering a glimpse into the venture market of the current year. But, before we delve into that, let me provide a quick recap of my action-packed 2023.